Optimizing Atrial fibrillation management from ICU and beyond

Chest

Volumn 148, Issue 4, 2015, Pages 859-864

  Walkey, Allan J ^a   Hogarth, D Kyle ^b   Lip, Gregory Y H ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; MAGNESIUM;

CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HEART HEMODYNAMICS; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE; LONG TERM CARE; NEW-ONSET ATRIAL FIBRILLATION; OUTPATIENT; PATIENT ASSESSMENT; PATIENT RISK; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; DISEASE MANAGEMENT; INTENSIVE CARE UNIT; PROCEDURES;

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; DISEASE MANAGEMENT; HUMANS; INTENSIVE CARE UNITS;

EID: 84943421376     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0358     Document Type: Note

References (45)

1. Annane D, Sébille V, Duboc D, et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 2008; 178 (1): 20-25.
2. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011; 306 (20): 2248-2254.
3. Walkey AJ, Greiner MA, Heckbert SR, et al. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J. 2013 ;165(6):949-955.
4. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005; 128 (4): 2864-2875.
5. Walkey AJ, Ambrus D, Benjamin EJ. The role of arrhythmias in defining cardiac dysfunction during sepsis. Am J Respir Crit Care Med. 2013; 188 (6): 751.
6. Arrigo M, Bettex D, Rudiger A. Management of atrial fibrillation in critically ill patients. Crit Care Res Pract. 2014 ;2014:840615.
7. Kanji S, Stewart R, Fergusson DA, McIntyre L, Turgeon AF, Hébert PC. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008; 36 (5): 1620-1624.
8. Krijthe BP, Heeringa J, Kors JA, et al. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013; 168 (6): 5411-5415.
9. Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2013; 127 (1): 33-38.
10. Ninio DM, Saint DA. The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol. 2008; 97 (2-3): 401-416.
11. Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm. 2011; 8 (9): 1436-1443.
12. January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64 (21): e1-e76.
13. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33 (21): 2719-2747.
14. Mayr A, Ritsch N, Knotzer H, et al. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med. 2003; 31 (2): 401-405.
15. Meierhenrich R, Steinhilber E, Eggermann C, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care. 2010; 14 (3): R108.
16. Ang EL, Chan WL, Cleland JG, et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J. 1990; 64 (4): 256-260.
17. Delle Karth G, Geppert A, NeunteuflT, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias . Crit Care Med. 2001; 29 (6): 1149-1153.
18. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recentonset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995; 16 (4): 521-528.
19. Souney PF, Cooper WD, Cushing DJ. PM101: intravenous amiodarone formulation changes can improve medication safety. Expert Opin Drug Saf. 2010; 9 (2): 319-333.
20. Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ. The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period. Clin Exp Pharmacol Physiol. 2010; 37(3): 358-361.
21. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989; 63 (13): 925-929.
22. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997; 29 (1): 135-140.
23. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007; 99 (12): 1726-1732.
24. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. I nt J Cardiol. 2001; 79 (2-3): 287-291.
25. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995; 23 (11): 1816-1824.
26. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310 (16): 1683-1691.
27. Lubitz SA, Yin X, Rienstra M, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015; 131 (19): 1648-1655.
28. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest. 2014; 146 (5): 1187-1195.
29. Gialdini G, Nearing K, Bhave PD, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA. 2014; 312 (6): 616-622.
30. Walkey AJ. Preventing cardiovascular complications of acute infection: a missed opportunity ? Circulation. 2014; 129 (13): 1375-1377.
31. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014; 370 (26): 2478-2486.
32. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994; 89 (1): 224-227.
33. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost. 2014; 112 (2): 276-286.
34. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168(5): 4744-4749.
35. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. C irc J. 2012; 76 (10): 2289-2304.
36. Nieuwlaat R, Capucci A, Lip GY, et al; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27 (24): 3018-3026.
37. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation . Nat Rev Cardiol. 2011; 8 (10): 602-606.
38. Lip GY, Lane DA. Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. Circ J. 2014; 78 (8): 1843-1845.
39. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110 (6): 1087-1107.
40. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013; 144 (5): 1555-1563.
41. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014; 127 (11): 1083-1088.
42. Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014; 9 (4): 443-447.
43. Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT 2 R 2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014; 146 (3): 719-726.
44. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014; 160 (11): 760-773.
45. Chung MK, Shemanski L, Sherman DG, et al; AFFIRM Investigators. Functional status in rate- versus rhythmcontrol strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol. 2005; 46 (10): 1891-1899.